Thanks again for your insights Ben. Truely appreciate your...

First 29 Last

Share
Profile

Follow
Stungun

448 Posts.

73

30/06/23

09:22

Post #: 68546797
Share

Originally posted by Watmighthavben: ↑

Her Vaxx has often been viewed as a comparable if not better drug than Roche's Herceptin, given not only its outstanding overall survival rates (OSR) but it's strong safety parameters. With peak sales of approximately $6 billion USD Herceptin may well have been worth close to $25 billion USD to the Roche pharmaceutical company. That's a value equivalent in excess of $5 per IMU share when taking Imugene's current market cap and shares on offer into consideration. Yes the HER 2 market is a more competitive space than when Herceptin first arrived and reached peak sales, but it shows how completely ridiculous the IMU share price is at these levels.

To think a Big Pharma, hedge fund or large Asian investor is not going to pay north of $5bn USD for a piece of the her Vaxx and B Cell pie is fanciful. It is no doubt looking like Merck, as they are in combination with Her Vaxx via the Keytruda route, but I wouldn't be ruling out Roche (in combination with PD1 Vaxx) or Pfizer either. Like PD1 Vaxx, which in my mind is an awesome drug trialling in one of the world's largest cancer markets (i.e., lung cancer), Her Vaxx is going to have significant interest as the medical world awakes to its huge combination potential. Low costs of manufacturing, little or no toxicity and the potential to treat a vast array of cancer indications in are all upside for the acquirer.

This time last year when the Her Vaxx overall survival rates were announced IMU was three times the price it is today. OSR results are even better now and Imugene's clinical trials are far more advanced than they were back then. This stock is due for serious rerate in July.

DYOR Seek investment advice as and when required Opinions only

Expand

Thanks again for your insights Ben. Truely appreciate your posts.

IMU Price at posting: 8.9¢ Sentiment: Buy Disclosure: Held
22 Upvote

0 Great analysis

Reply

Top Stories

ASX200 dives as inflation clocks in at 4% – higher than 3.8% consensus

NXM

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

SS1

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

SFX

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

NIM

Nimy extends sulphide targets at Mons with new anomalies identified

There are more pages in this discussion • 128 more messages in this thread...

First 29 Last

Add IMU (ASX) to my watchlist

(20min delay)
Last 5.4¢		Change -0.003(5.26%)		Mkt cap ! $395.2M

Open	High	Low	Value	Volume
5.5¢	5.7¢	5.4¢	$1.444M	26.24M

Buyers (Bids)

No.	Vol.	Price($)
24	3824179	5.4¢

Sellers (Offers)

Price($)	Vol.	No.
5.5¢	172983	1

View Market Depth

No.	Vol.	Price($)
24	3824179	0.054
13	2500789	0.053
20	1688241	0.052
23	3475256	0.051
64	4520234	0.050

Price($)	Vol.	No.
0.055	172983	1
0.056	1170000	3
0.057	2018516	13
0.058	2633548	15
0.059	4056569	12

Last trade - 16.10pm 27/06/2024 (20 minute delay)

IMU (ASX) Chart

Thanks again for your insights Ben. Truely appreciate your...

ASX200 dives as inflation clocks in at 4% – higher than 3.8% consensus

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

Nimy extends sulphide targets at Mons with new anomalies identified

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks again for your insights Ben. Truely appreciate your...

Top Stories

ASX200 dives as inflation clocks in at 4% – higher than 3.8% consensus

Drilling at Bethanga shows signs of Cu-Au porphyry system for Nexus

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

Sheffield Resources achieves milestone production, shipments at Thunderbird, WA

Nimy extends sulphide targets at Mons with new anomalies identified

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News